Overview

Renal Impairment in Type 2 Diabetic Subjects

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin